News | January 31, 2025
Strides reports 14.6% growth in Q3 FY25 revenue
EBITDA grew 46.9% YoY to Rs. 210.3 crore with EBITDA margin at 18.2%, grew 401 bps YoY and the reported PAT at Rs. 90 crore
EBITDA grew 46.9% YoY to Rs. 210.3 crore with EBITDA margin at 18.2%, grew 401 bps YoY and the reported PAT at Rs. 90 crore
The transaction is part of a broader agreement with Bureau Veritas covering its worldwide food laboratory testing activities
Consequent to this appointment, Sarosh Shetty ceases to be Interim CEO of ICH.
Wockhardt plans to launch Miqnaf in the Indian market in coming few months
Brings together industry experts to discuss preventive steps to protect pigs from African swine fever and best practises for pig farm management
Iskra has held leadership positions across Central & Eastern Europe, Eurasia, Middle East & Africa at AstraZeneca
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer
This agreement reinforces Lubrizol’s commitment to Make-In-India and broadens a previously committed US$ 350 million investment to support local manufacturing
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
Subscribe To Our Newsletter & Stay Updated
